Please login to the form below

Not currently logged in
Email:
Password:

Neuraceq

This page shows the latest Neuraceq news and features for those working in and with pharma, biotech and healthcare.

EMA unveils draft guidelines for Alzheimer’s disease research

EMA unveils draft guidelines for Alzheimer’s disease research

Although the last few years have seen a number of Alzeimer's diagnostics approved, among them GE Healthcare Vizamyl (flutemetamol) and Piramal's Neuraceq (florbetaben F18), research progress for a treatment

Latest news

  • CHMP backs Piramal's Alzheimer's imaging agent CHMP backs Piramal's Alzheimer's imaging agent

    Neuraceq recommended for approval in Europe. Piramal is close to winning EU approval for its Alzheimer's disease (AD) diagnostic Neuraceq after a positive opinion from the EMA's Committee for ... Piramal acquired rights to Neuraceq from Bayer in 2012,

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics